Call for Grant Applications on Evolving Treatment Options in First-Line Metastatic Urothelial Carcinoma and Muscle Invasive Bladder Cancer
Pfizer Inc. funds independent education projects to advance clinical knowledge and practice in first-line treatment of metastatic urothelial carcinoma and muscle invasive bladder cancer.
Funder: Pfizer Inc.
Due Dates: September 6, 2026
Funding Amounts: US$10,000–US$150,000 per project | Total program budget: US$450,000 | Project period: typically October 2026–January 2027
Summary: Funds independent medical education initiatives to improve knowledge and practice among healthcare professionals treating metastatic urothelial carcinoma and muscle invasive bladder cancer.
Key Information: Only organizations (not individuals) are eligible; US is not a priority geography, and applications from Japan, Italy, and South Korea are not accepted.
Description
This grant, offered by the Pfizer-Astellas Alliance, supports independent medical education projects aimed at healthcare professionals who manage patients with locally advanced/metastatic urothelial carcinoma (la/mUC) and muscle invasive bladder cancer (MIBC). The goal is to address knowledge gaps and accelerate the adoption of emerging clinical data and best practices, especially in first-line treatment, therapeutic sequencing, adverse event management, and multidisciplinary care. Projects may include curriculum-based learning, live or online sessions, tumor boards, and innovative educational formats, with a focus on holistic patient care and improved outcomes.
